Cannara Biotech Inc. is on the rise, with a notable gain of 1.22% in the last trading session.
Cannara Biotech Inc. (LOVE.TO) closed at CA$1.66 after a 1.22% increase. This uptick follows promising financial performance and strategic moves aimed at expanding its market presence.
Advertisement
Earn cash back with a smarter spending account
Open a KOHO account and start earning on everyday purchases — no annual fee on the base plan.
Cannara Biotech Inc.
LOVE.TO
LOVE.TO
Cannara Biotech Inc.
WealthAwesomeMarket cap
$187.69M
P/E
17.3x
52W high
$2.05
52W low
$1.55
1W change
+1.60%
Beta
0.35
Analyst Price Targets
Based on analyst covering LOVE
Wall Street analysts forecast LOVE stock price to rise 76.7% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$3.38
+76.7% Upside
Current Price
C$1.91
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on LOVE's historical volatility
30-Day Vol
40.3%
Annualized
90-Day Vol
36.1%
Annualized
Trend (90d)
+34.4%
Annualized drift
90d Mean
C$2.16
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$1.99 | C$1.73 – C$2.29 |
| 60 trading days | C$2.07 | C$1.70 – C$2.52 |
| 90 trading days | C$2.16 | C$1.70 – C$2.75 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Investor takeaway: With a market cap of CA$164.97 million and a P/E ratio of 15.09, Cannara Biotech's recent performance and strategic initiatives may signal growing confidence among investors.
Cannara Biotech Inc. Gains 1.22% in Last Session
The stock's recent performance reflects increasing investor confidence, supported by the company's strong financial results and strategic initiatives.
Bull case
The company recently reported record revenues of CA$107.3 million for Fiscal 2025, along with a net income of CA$13.1 million. This indicates strong operational growth and profitability.
Bear case
Despite the positive performance, investors should stay cautious. The cannabis sector remains volatile and is subject to regulatory changes that could affect future growth.
Recent Performance Highlights
Advertisement
Cannara Biotech's stock closed at CA$1.66, reflecting a 1.22% increase in the last trading session. This positive movement comes as the company builds on its recent successes, including record revenues and profitability.
Strategic Initiatives Boosting Confidence
The company has achieved significant milestones, such as DTC eligibility, which enhances accessibility for U.S. investors, and a successful debt-to-equity conversion. These moves are expected to strengthen Cannara's balance sheet and investor appeal.
Looking Ahead
As Cannara prepares to release its Q3 2025 financial results on July 28, 2025, investors are keenly watching for further insights into the company’s growth trajectory and market strategies. The upcoming announcements could provide additional catalysts for stock performance.
Advertisement
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
